Psychiatric treatment considerations with direct acting antivirals in hepatitis C - Wikidata - awgldk - TriplyDB

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

http://www.wikidata.org/entity/Q34721628

about

Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study.Drug-drug interactions involving antidepressants: focus on desvenlafaxine.

P2860

Q26798477-01406DC9-1E4E-4AB3-8BC9-2B911FFFC84F Q34143327-1288C637-A1F3-4DBC-9552-054E335EF7E2 Q36137527-C85940D2-F37C-476C-8786-CAA1B4E2888E Q47553759-DA3B86C8-5D38-4E19-B913-BFCA7E7F80B5 Q52369980-735C8973-301A-48B5-B1CA-0BB84B849388

P2860

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

http://www.wikidata.org/entity/Q34721628

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@ast

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@en

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@nl

type

label

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@ast

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@en

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@nl

prefLabel

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@ast

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@en

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@nl

P1433

Q34721628-FF83E8BA-D74B-4E38-AA1E-C5569F904DB8

P1476

Q34721628-91668437-F013-49DC-9C87-2686A8C19B40

P2093

Q34721628-24D69FE3-B8AD-480B-A09E-0001EDBB9BF3

Q34721628-28BF019B-260D-44E3-9C67-B2B53512F77A

Q34721628-7A6C9EBD-E29B-49F9-8179-E93F534A69C3

Q34721628-B8DF5E7C-9124-4662-981B-E5D2DA034BAF

P275

Q34721628-CF3E7F58-38C5-45DE-9F6F-758371A90EEA

P2860

Q34721628-020C0A06-5616-4225-8F33-AECCC9AFD9F1

Q34721628-0556B9FE-4E85-414B-8894-9AB7A57D95AE

Q34721628-077988C7-4B89-4586-956D-9691006639B9

Q34721628-08AF740D-8CD3-490A-8BB2-F17EE52FF8A2

Q34721628-0AD9B95A-67CA-4115-AE3E-5D5F86A0E6EA

Q34721628-0C6B204A-DCDE-46A3-A98E-C1AEA152F231

Q34721628-13AFCAC4-11F0-4670-9344-1FF469713619

Q34721628-15ABA9DD-AEA9-4303-B527-44E0ADC964C1

Q34721628-160D5F7C-CA5A-4BF4-9A5A-24A0400FD9F2

Q34721628-17BBCD97-9F6A-4C73-80ED-F5D647EBA697

P2888

Q34721628-F07262B8-C1DF-4ECF-AF5B-6DA55B7612E2

P304

Q34721628-30AB5005-A9C1-4BFA-8708-24DD70428D18

P31

Q34721628-304A0E65-A455-4A16-BCA9-E7ADC76840DE

Q34721628-DD58021B-8FF6-4534-BF44-D7D98306CEF8

P356

Q34721628-FD602350-C552-4512-B468-600062AD23D2

P478

Q34721628-F9B6EB16-A1B1-41E8-A313-FA4C422918C8

P5008

Q34721628-DC87D9CE-4C09-4F95-858A-F4C59B7771F0

P577

Q34721628-AF639836-4490-42C1-813A-F5B3B0F11FD3

P5875

Q34721628-F5EA8881-D354-42CA-B4E8-BFC89BE11062

P6179

Q34721628-2F8DE9D5-B81F-4E63-A9DF-BC94FB17E49F

P698

Q34721628-F9346BE3-F89B-4ABD-B7ED-5FE4D81EE5F1

P921

Q34721628-748CE451-7A59-49FF-85C8-C2F4C2FA5794

Q34721628-DDAF6952-F5BB-483C-AD5A-665AB31524FD

Q34721628-EE0B2C9A-FA84-4C2B-8141-F03E1CC417A3

P932

Q34721628-846F4BC8-DC4B-4DFF-8168-0C7FFE8E8B4A

P356

1471-230X-13-86

P1433

BMC Gastroenterology

P1476

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

@en

P2093

Alice Tseng

http://www.w3.org/2001/XMLSchema#string

David Wong

http://www.w3.org/2001/XMLSchema#string

Pierre Giguere

http://www.w3.org/2001/XMLSchema#string

Sanjeev Sockalingam

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

QT interval and antidepressant use: a cross sectional study of electronic health records

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Epidemiology of hepatitis C: geographic differences and temporal trends

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Boceprevir for untreated chronic HCV genotype 1 infection

Psychiatric comorbidity among hepatitis C-positive patients.

Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia.

P2888

1471-230x-13-86

P304

86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-230X-13-86

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236835396

http://www.w3.org/2001/XMLSchema#string

P6179

1026649035

http://www.w3.org/2001/XMLSchema#string

P698

23672254

http://www.w3.org/2001/XMLSchema#string

P921

mental disorder

physiological phenomena

P932

3658966

http://www.w3.org/2001/XMLSchema#string